Every 10-Q that BODHI TREE BIOTECHNOLOGY (BDTB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BDTB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDTB filings page.
Bodhi Tree Biotechnology Inc. reported minimal but growing operations for the quarter and nine months ended June 30, 2026. Revenue for the nine-month period was $25,000, up from $5,000 a year earlier, with a net loss of $105,338 versus $138,979 in the prior-year period. For the quarter, revenue was $10,000 and the net loss was $23,194.
Cash declined sharply to $3,986 at June 30, 2026 from $109,404 at September 30, 2025, driven by $105,418 of net cash used in operating activities. Total assets were $18,323, with no debt and an accumulated deficit of $316,957. A majority shareholder has provided a written commitment to fund working capital through unsecured loans, which management believes alleviates substantial doubt about continued operations under the going concern framework.
The company remains pre-revenue scale, with highly concentrated sales among a few customers and no cost of revenues recognized. During the quarter, its common stock was approved for quotation on the OTCQB Venture Market, and subsequent to quarter-end it signed a $161,491 product sampling and trial production contract. Management disclosed material weaknesses in internal control over financial reporting, citing limited U.S. GAAP expertise and lack of segregation of duties.
Bodhi Tree Biotechnology Inc. reported a small but growing consulting business with continued losses for the quarter and six months ended March 31, 2026. Revenue for the six-month period was $15,000, up from $5,000 a year earlier, all from a single individual customer. General and administrative expenses were $95,883, down from $121,956, reflecting mainly professional fees and overhead.
The company recorded a six-month net loss of $82,144, an improvement from a $118,205 loss in the prior-year period, and used $86,654 of cash in operating activities. Cash declined to $22,750 and total assets to $40,517 as of March 31, 2026, while liabilities remained minimal at $3,500 of accrued expenses. Stockholders’ equity fell to $37,017.
Bodhi Tree has 25,441,042 common shares outstanding and relies on a highly concentrated revenue base. Management plans to fund operations through securities offerings or other financing. During the quarter, its common stock was approved for quotation on the OTCQB Venture Market. Management also reported material weaknesses in internal control over financial reporting, citing limited US GAAP knowledge and lack of segregation of duties.
Bodhi Tree Biotechnology Inc. reported a net loss of $52,948 for the three months ended December 31, 2025, compared with a $64,777 loss a year earlier. The company generated no revenue in the quarter, versus $5,000 in the prior-year period, as it builds its vegetarian menu and diet consulting business.
Cash declined to $47,366 from $109,404 at September 30, 2025, with total assets of $69,713 and stockholders’ equity of $66,213. Accumulated deficit reached $264,567, and operations were funded entirely by existing capital.
Management disclosed material weaknesses in internal control over financial reporting, citing limited U.S. GAAP expertise and insufficient segregation of duties. During the quarter, the company’s application to have its common stock quoted on the OTCQB Venture Market was approved, and certain share legends were removed to increase public float.